KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers
May 11, 2020 10:30 amBy Ian Ingram
For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.
Among women treated with … Read more